Now online

11-12 November 2020

Day 1: Wednesday 11th November 2020

12:30	**Welcome and Introductions** Tom Heightman, *Vice President Oncology Chemistry, AstraZeneca and Helen Pain, Acting CEO, Royal Society of Chemistry*
	Session 1: (Session Chair: Tom Heightman, Vice President Oncology Chemistry, AstraZeneca)
12:45	**Sustainable Catalytic Methodologies for Synthesis** Dr Louis C. Morrill *University of Cardiff, UK*
13:20	**Alkylation using Acids and Alcohols** Professor Ross Denton *University of Nottingham, UK*
13:55	**AstraZeneca lecture: Development of a New Route to Ceralasertib Using a Continuous Flow Photoredox Minisci Process** Dr Mark Graham *Associate Principal Scientist*
14:30	Coffee break and Breakout Sessions*

	Session 2: (Session Chair: Gail Wrigley, *Associate Principal Scientist, Medicinal chemistry, Oncology chemistry, AstraZeneca*)
15:10	**Enabling synthesis in FBDD with emerging technologies** Dr Charlotte Griffiths-Jones *Astex Therapeutics*
15:45	**GenoChemetics – blending synthetic biology with synthetic chemistry for molecule making** Professor Rebecca Goss *University of St Andrews, UK*
16:25	**Concluding Remarks** Gail Wrigley *AstraZeneca*

Day 2: Thursday 12th November 2020

12:30	**Welcome and Introductions** Jeremy Parker, *Head of Early Chemical Development, AstraZeneca and Helen Pain, Acting CEO, Royal Society of Chemistry*
	Session 1: (Session Chair: Jeremy Parker, *Head of Early Chemical Development, AstraZeneca*)
12:45	**Academic synthesis with applied purpose** Dr Allan Watson *University of St Andrews, UK*
13:20	**Application of innovative synthetic methods in the discovery of ATAD2 inhibitors** Clare Gregson *AstraZeneca*
13:55	**Biocatalytic Approaches to Complex Targets** Dr Elaine O'Reilly, *University College Dublin, Ireland*
14:30	Coffee and Breakout Sessions*

	Session 2: (Session Chair: Mark Purdie, *Principal Scientist, Chemical Development, AstraZeneca*)
15:10	**Catalysis using metal(loid) hydrides** Dr Stephen Thomas *University of Edinburgh, UK*
15:45	**Harnessing Non-Covalent Interactions to Address Selectivity Challenges in Catalysis** AstraZeneca Chemistry Award: Dr Robert Phipps University of Cambridge, UK
16:25	**Concluding Remarks** Mark Purdie, *Principal Scientist, Chemical Development, AstraZeneca* and Helen Pain, *Acting CEO, Royal Society of Chemistry*
16:35	**Close of Sessions**

*****Please see separate programme for the Breakout sessions